CLOSE
For adults with open-angle glaucoma or ocular hypertension
Rocklatan® has been acquired by Alcon, the Global Leader in Eye Care. Learn more
Contraindications
None.
Warnings and Precautions
Rocklatan® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as Rocklatan® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.
Rocklatan® should be used with caution and may cause inflammation inside the eye or make existing inflammation worse.
Rocklatan® may cause macular edema (swelling of the macula) and should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.
Rocklatan® should be used with caution in patients with a history of herpetic keratitis and not used in patients with active herpes simplex keratitis.
Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.
Contact lenses should be removed prior to using Rocklatan®. Contact lenses can be reinserted 15 minutes following administration of Rocklatan®.
If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing treatment with Rocklatan®.
Adverse reactions
The most common side effect for Rocklatan® in controlled clinical studies were red eyes (59%). Five percent of patients discontinued therapy due to red eyes. Other common side effects were pain upon instillation of eye drop (20%), small deposits on the outer surface of the eye (corneal verticillata) (15%), and broken blood vessels (11%). Eye itching, visual acuity reduced, excessive tearing, eye discomfort upon administration of eye drop, and blurred vision were reported in 5-8% of patients.
Be sure to contact your doctor if you have any questions.
Please click here for full prescribing information for Rocklatan®.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Contraindications
None.
Warnings and Precautions
Rocklatan® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as Rocklatan® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.
Rocklatan® should be used with caution and may cause inflammation inside the eye or make existing inflammation worse.
Rocklatan® may cause macular edema (swelling of the macula) and should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.
Rocklatan® should be used with caution in patients with a history of herpetic keratitis and not used in patients with active herpes simplex keratitis.
Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.
Contact lenses should be removed prior to using Rocklatan®. Contact lenses can be reinserted 15 minutes following administration of Rocklatan®.
If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing treatment with Rocklatan®.
Adverse reactions
The most common side effect for Rocklatan® in controlled clinical studies were red eyes (59%). Five percent of patients discontinued therapy due to red eyes. Other common side effects were pain upon instillation of eye drop (20%), small deposits on the outer surface of the eye (corneal verticillata) (15%), and broken blood vessels (11%). Eye itching, visual acuity reduced, excessive tearing, eye discomfort upon administration of eye drop, and blurred vision were reported in 5-8% of patients.
Be sure to contact your doctor if you have any questions.
Please click here for full prescribing information for Rocklatan®.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
